Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OST-122 in moderate to severe ulcerative colitis
NCT04353791Phase 2Completed
- Sponsor
- Oncostellae
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of OST-122 in ulcerative colitis (UC), sponsored by Oncostellae. Started Sep 2020; status: completed.
02
Drugs
OST-122
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04353791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353791.